Tests PSMA-targeted CAR-T cell therapy for advanced prostate cancer
Tests modified immune cells against prostate cancer in adults with castration-resistant disease.
Plain-language title generated from the registry record
Registry title: Clinical Study of PSMA-targeted CAR-T Cells in the Treatment of Castration-resistant Prostate Cancer
Key facts
- Where
- Xuzhou, ChinaSee the site
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT05354375, who can take part
Where in China
- Affiliated Hospital of Xuzhou Medical UniversityXuzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The Affiliated Hospital of Xuzhou Medical University
- Trial code
- NCT05354375
- Record updated
- 29 April 2022
- Original description
This is an experimental study to evaluate the safety and effectiveness of PSMA-targeted CAR-T cells in the treatment of castration-resistant prostate cancer.Read full original descriptionShow less
Clinical Study of PSMA-targeted CAR-T Cells in the Treatment of Castration-resistant Prostate Cancer
This is an experimental study to evaluate the safety and effectiveness of PSMA-targeted CAR-T cells in the treatment of castration-resistant prostate cancer.
Inclusion: Male patients aged from 18 to 75 years old; The patients' ECOG score ≤ 2; Prostate cancer patients in castration resistance stage (with or without distant metastasis):; Previous new endocrine therapy is ineffective; Past treatment with too much citabine or cabatase is ineffective; Have measurable or evaluable lesions; The patients' main tissues and organs function well:; Liver function: ALT/AST < 3 times the upper limit of normal value (ULN); renal function: creatinine < 220 μ mol/L; Lung function: indoor oxygen saturation ≥ 95%; Cardiac function: Left ventricular ejection fraction (LVEF)≥40%; Patients or their legal guardians voluntarily participate and sign the informed consent form.
Exclusion: Infectious diseases (such as HIV, active hepatitis B or C infection, active tuberculosis, etc.); Those with mental illness or mental illness who can't cooperate with treatment and curative effect evaluation; Highly allergic constitution or severe allergic history, especially those who are allergic to IL-2; Subjects with systemic infection or local severe infection who need anti-infection treatment; Complicated dysfunction of heart, lung, brain, liver, kidney and other important organs; Feasibility evaluation screening proves that the transfection of targeted lymphocytes is less than 10% or the amplification under the co-stimulation of CD3/CD28 is insufficient (< 5 times); The vital signs are abnormal and those who cannot cooperate with the inspectors; Patients with other tumors; Doctors think that there are other reasons that can't be included in the treatment.